| scholarly article | Q13442814 |
| P50 | author | Alexander Th Wu | Q63229815 |
| Debabrata Mukhopadhyay | Q88258080 | ||
| Chien-Min Lin | Q90334989 | ||
| Michael Hsiao | Q46884406 | ||
| Oluwaseun Adebayo Bamodu | Q47600753 | ||
| P2093 | author name string | Li Wei | |
| Yun Yen | |||
| Hsu-Shan Huang | |||
| Tsu-Yi Chao | |||
| Ya-Ting Wen | |||
| P2860 | cites work | Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. | Q55475013 |
| Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma | Q57153312 | ||
| NF-κB, Mesenchymal Differentiation and Glioblastoma | Q58779206 | ||
| Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity | Q58798205 | ||
| RANKL inhibition—a new weapon against breast cancer? | Q60406373 | ||
| Role of the nervous system in cancer metastasis | Q89873187 | ||
| Temozolomide resistance in glioblastoma multiforme | Q91792247 | ||
| Restoring the oncosuppressor activity of microRNA-34a in glioblastoma using a polyglycerol-based polyplex | Q42119458 | ||
| MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review | Q46249299 | ||
| Monoamines in Glioblastoma: complex biology with therapeutic potential. | Q47617131 | ||
| RANKL and RANK: From Mammalian Physiology to Cancer Treatment. | Q48568949 | ||
| Eva1 Maintains the Stem-like Character of Glioblastoma-Initiating Cells by Activating the Noncanonical NF-κB Signaling Pathway. | Q49136615 | ||
| Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. | Q50089383 | ||
| Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells. | Q50645523 | ||
| NF-κB Signalling in Glioblastoma. | Q52091959 | ||
| Current Challenges and Opportunities in Treating Glioblastoma. | Q52579808 | ||
| NFκB activation in differentiating glioblastoma stem-like cells is promoted by hyaluronic acid signaling through TLR4. | Q55282732 | ||
| A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion | Q24633772 | ||
| Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance | Q26765869 | ||
| Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons | Q26852122 | ||
| Epidemiologic and molecular prognostic review of glioblastoma | Q28395302 | ||
| Overcoming therapeutic resistance in glioblastoma: the way forward | Q29248396 | ||
| MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes | Q30434616 | ||
| Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways | Q33764768 | ||
| miR-34 - a microRNA replacement therapy is headed to the clinic | Q34640230 | ||
| Shaping the interaction landscape of bioactive molecules. | Q34992054 | ||
| Chemoresistance of glioblastoma cancer stem cells--much more complex than expected | Q35521316 | ||
| Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells | Q35586803 | ||
| Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells | Q36051827 | ||
| Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma | Q36401854 | ||
| The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence | Q36795940 | ||
| Temozolomide promotes genomic and phenotypic changes in glioblastoma cells. | Q36875981 | ||
| Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors | Q37250253 | ||
| The role of microRNAs in the regulation of cancer stem cells | Q37428403 | ||
| IKK/nuclear factor-kappaB and oncogenesis: roles in tumor-initiating cells and in the tumor microenvironment | Q38216986 | ||
| Glioblastoma targeted therapy: updated approaches from recent biological insights | Q38597700 | ||
| Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases | Q38752122 | ||
| Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma | Q38838354 | ||
| Discovery of 5-(2',4'-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis | Q38871402 | ||
| Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling | Q38969940 | ||
| CD133 is essential for glioblastoma stem cell maintenance. | Q39212552 | ||
| Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation. | Q39280197 | ||
| Glioblastoma | Q40869087 | ||
| Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging | Q41969010 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P921 | main subject | glioblastoma | Q282142 |
| P577 | publication date | 2019-09-26 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis | |
| P478 | volume | 11 |
Search more.